Mabion S.A. in the news

Mabion S.A. disclosed its 2026 financial report publication dates, including annual and quarterly reports.

Mabion secured a €3.1 million convertible loan from CBC to improve liquidity and support corporate goals amid its shift to a biologic CDMO.

Mabion and WPD Pharmaceuticals plan to jointly develop innovative ADC molecules, expanding Mabion's biologics services in line with its 2025-2030 strategy.

Mabion and Celon Pharma plan a strategic partnership to jointly develop ADC products, combining Mabion's protein expertise with Celon's conjugation technology.

Mabion S.A. and WPD Pharmaceuticals S.A. signed a letter of intent to jointly develop oncology biological medicinal products, specifically focusing on antibody-drug conjugates, by October 1, 2026.

Mabion SA will release its next earnings report on November 17, 2026, with recent financial data showing negative net income and EBITDA, and the company currently employs 204 people.

Mabion SA, a company with 204 employees, has a stock ticker of '272' on the SWB exchange, reported a net loss of ‐3.47 M EUR last quarter, and does not pay dividends.

Mabion S.A. reported a mixed financial performance for Q2 and the first half of 2026, with Q2 sales declining but six-month sales and revenue increasing, while net losses narrowed in both periods.

Mabion S.A. reported a net loss of 24.68 million PLN for H1 2026 and their auditor refused to express an opinion on the financial statement.

Mabion will undergo a pivotal FDA inspection in November 2026, focusing on its analytical laboratories to gain access to US and international pharmaceutical markets.

Mabion S.A. increased revenue and reduced losses in H1 2026, while expanding globally, focusing on Drug Substance manufacturing, and planning a US acquisition.

Mabion S.A. reported a reduced net loss of PLN 24.68 million for the first half of 2026, improving from PLN 30.67 million in the previous year.

Mabion S.A. issued 2.56 million shares for PLN 17.05 million to convert loans from two Cypriot lenders, Twiti Investments Limited and ACRX Investments Limited.

Mabion is conducting due diligence for a potential acquisition of an FDA-approved US manufacturing facility specializing in mAbs and ADCs to expand its contract manufacturing operations in the US.

Mabion S.A. is exploring the acquisition of an FDA-approved biopharmaceutical manufacturing plant in the United States to expand its production capabilities and enter the US market.

Mabion S.A. is performing due diligence for a potential acquisition of an FDA-approved biopharmaceutical manufacturing plant in the United States to boost production capacity and enter the US market.

Mabion converted 17 million PLN of debt into equity with financial partners and secured an additional 24 million PLN in financing to strengthen its financial structure and support its development strategy.

Mabion converted 17 million PLN of debt into equity by issuing shares to financial partners, securing an additional 24 million PLN in financing to support its 2025-2030 strategy.

Mabion strengthened its financial structure by converting approximately PLN 17 million of debt into equity and securing an additional PLN 24 million in financing from TWITI Investments Limited and ACRX Investments Limited.

Mabion S.A. converted 17 million PLN of debt into equity and secured an additional 24 million PLN in funding from financial partners, strengthening its financial position for future growth.